Axiogenesis proudly co-sponsors the "Drug Discovery for Ion Channels" satellite meeting at the 60th annual meeting of the Biophysical Society - Feb 26, 2016

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. But the advent of automated electrophysiological systems with higher throughput has begun to revolutionize ion channel drug discovery. This symposium focuses on the emerging technology of automated electrophysiology and how it is changing the face of ion channel drug discovery. Speakers from industry and academia will discuss the development and potential of these new technologies, present experimental results obtained using these systems and discuss the impact these technologies are having on ion channel drug discovery.

Check out the agenda here

 

Join CHI's free Webinar "Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models"  sponsored by Axiogenesis

Webinar Description:

Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.

February 10, 2016
10 am to 11 am EST
4 pm to 5pm CET

For more details and to register please visit here

Schedule conflict? Register anyways and you'll receive a copy of the recording!

 

Cor.4U have electrophysiological parameters approaching adult human tissue

Axiogenesis Cor.4U human cardiomyocytes, serving as a human cellular model in a recent late stage pre-clinical safety study, demonstrated electrophysiological parameters approaching adult human tissue. The use of these Cor.4U cardiomyocytes was “consistent with the emphasis on (Multiple Ion Channel Effects) MICE of the CiPA assay”. The experimental paradigm presented by this study will be amodel for future drug safety screening efforts. 

For more details read the full article here

Application Workshop Material is Available for Download now

We thank our attendees, presenter and cooperation partners for their contribution to the success of this workshop. 

The conference material of our latest Application Workshop "Great Assays For hiPSC-derived Cardiomyocytes & Neurons", Nov 2015  is available here.

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany – (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10